187 related articles for article (PubMed ID: 20394851)
21. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
[TBL] [Abstract][Full Text] [Related]
22. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system.
Palazzi M; Tomatis S; Orlandi E; Guzzo M; Sangalli C; Potepan P; Fantini S; Bergamini C; Gavazzi C; Licitra L; Scaramellini G; Cantu' G; Olmi P
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):330-7. PubMed ID: 17881148
[TBL] [Abstract][Full Text] [Related]
23. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
[TBL] [Abstract][Full Text] [Related]
24. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
[TBL] [Abstract][Full Text] [Related]
26. Improved dosimetric and clinical outcomes with intensity-modulated radiotherapy for head-and-neck cancer of unknown primary origin.
Chen AM; Li BQ; Farwell DG; Marsano J; Vijayakumar S; Purdy JA
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):756-62. PubMed ID: 20421143
[TBL] [Abstract][Full Text] [Related]
27. Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
Allen AM; Elshaikh M; Worden FP; Bradford CR; Teknos TN; Chepeha DB; Tsien C; Dawson LA; Urba S; Wolf GT; Normolle D; Eisbruch A
Head Neck; 2007 Feb; 29(2):137-42. PubMed ID: 17111432
[TBL] [Abstract][Full Text] [Related]
28. Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage.
Al-Othman MO; Mendenhall WM; Amdur RJ
Am J Otolaryngol; 2001; 22(6):387-90. PubMed ID: 11713722
[TBL] [Abstract][Full Text] [Related]
29. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
30. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
[TBL] [Abstract][Full Text] [Related]
31. Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer.
Hartley A; Sanghera P; Kazi W; Mehanna H; McConkey C; Glaholm J; Fowler J
Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):29-33. PubMed ID: 20829006
[TBL] [Abstract][Full Text] [Related]
32. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.
Hehr T; Classen J; Welz S; Ganswindt U; Scheithauer H; Koitschev A; Bamberg M; Budach W
Radiother Oncol; 2006 Jul; 80(1):33-8. PubMed ID: 16875750
[TBL] [Abstract][Full Text] [Related]
33. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Wasserman TH; Brizel DM; Henke M; Monnier A; Eschwege F; Sauer R; Strnad V
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):985-90. PubMed ID: 16253773
[TBL] [Abstract][Full Text] [Related]
34. Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck.
Mendenhall WM; Riggs CE; Amdur RJ; Hinerman RW; Villaret DB
Laryngoscope; 2003 Mar; 113(3):546-51. PubMed ID: 12616212
[TBL] [Abstract][Full Text] [Related]
35. Physical and psychological symptoms of quality of life in the CHART randomized trial in head and neck cancer: short-term and long-term patient reported symptoms. CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy.
Griffiths GO; Parmar MK; Bailey AJ
Br J Cancer; 1999 Dec; 81(7):1196-205. PubMed ID: 10584882
[TBL] [Abstract][Full Text] [Related]
36. Early experience with a hybrid accelerated radiotherapy schedule for locally advanced head and neck cancer.
Nuyts S; Dirix P; Hermans R; Poorten VV; Delaere P; Weltens C; Van den Bogaert W
Head Neck; 2007 Aug; 29(8):720-30. PubMed ID: 17315171
[TBL] [Abstract][Full Text] [Related]
37. Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions.
Suwinski R; Bankowska-Wozniak M; Majewski W; Sowa A; Idasiak A; Ziolkowska E; Windorbska W; Tarnawski R; Skladowski K; Maciejewski B
Radiother Oncol; 2005 Oct; 77(1):58-64. PubMed ID: 16157401
[TBL] [Abstract][Full Text] [Related]
38. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03.
Rabinovitch R; Grant B; Berkey BA; Raben D; Ang KK; Fu KK; Cooper JS;
Head Neck; 2006 Apr; 28(4):287-96. PubMed ID: 16287132
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
Franchin G; Vaccher E; Gobitti C; Minatel E; Politi D; Talamini R; Di Gennaro G; Savignano G; Trovò MG; Tirelli U; Barzan L
Oral Oncol; 2005 May; 41(5):526-33. PubMed ID: 15878759
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
